NCT00510510 - Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

281

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

NVA237 100 µg

Dry powder inhalation once a day for up to 28 days

DRUG

Placebo

Placebo to NVA237 dry powder inhalation once a day for up to 28 days

DRUG

NVA237 200 µg

Dry powder inhalation once a day for up to 28 days

Trial Locations (21)

19713

Novartis investigative site, Newark

28207

Novartis investigative site, Charlotte

29303

Novartis investigative site, Spartanburg

29379

Novartis investigative site, Union

33143

Novartis investigative site, Miami

33169

Novartis investigative site, Miami

33321

Novartis investigative site, Tamarac

60305

Novartis investigative site, River Forest

63301

Novartis investigative site, Saint Chares

76104

Novartis investigative site, Fort Worth

77024

Novartis investigative site, Houston

80033

Novartis investigative site, Wheat Ridge

85006

Novartis investigative site, Phoenix

85306

Novartis investigative site, Glendale

97213

Novartis investigative site, Portland

66210-2761

Novartis investigative site, Overland Park

Unknown

Novartis investigative site, Rueil-Malmaison

Novartis investigative site, Nuremberg

Novartis investigative site, Arnhem

Novartis investigative site, Barcelona

Novartis investigative site, Istanbul